Töllner, M.; Speer, C.; Benning, L.; Bartenschlager, M.; Nusshag, C.; Morath, C.; Zeier, M.; Süsal, C.; Schnitzler, P.; Schmitt, W.;
et al. Impaired Neutralizing Antibody Activity against B.1.617.2 (Delta) after Anti-SARS-CoV-2 Vaccination in Patients Receiving Anti-CD20 Therapy. J. Clin. Med. 2022, 11, 1739.
https://doi.org/10.3390/jcm11061739
AMA Style
Töllner M, Speer C, Benning L, Bartenschlager M, Nusshag C, Morath C, Zeier M, Süsal C, Schnitzler P, Schmitt W,
et al. Impaired Neutralizing Antibody Activity against B.1.617.2 (Delta) after Anti-SARS-CoV-2 Vaccination in Patients Receiving Anti-CD20 Therapy. Journal of Clinical Medicine. 2022; 11(6):1739.
https://doi.org/10.3390/jcm11061739
Chicago/Turabian Style
Töllner, Maximilian, Claudius Speer, Louise Benning, Marie Bartenschlager, Christian Nusshag, Christian Morath, Martin Zeier, Caner Süsal, Paul Schnitzler, Wilhelm Schmitt,
and et al. 2022. "Impaired Neutralizing Antibody Activity against B.1.617.2 (Delta) after Anti-SARS-CoV-2 Vaccination in Patients Receiving Anti-CD20 Therapy" Journal of Clinical Medicine 11, no. 6: 1739.
https://doi.org/10.3390/jcm11061739
APA Style
Töllner, M., Speer, C., Benning, L., Bartenschlager, M., Nusshag, C., Morath, C., Zeier, M., Süsal, C., Schnitzler, P., Schmitt, W., Bergner, R., Bartenschlager, R., Lorenz, H.-M., & Schaier, M.
(2022). Impaired Neutralizing Antibody Activity against B.1.617.2 (Delta) after Anti-SARS-CoV-2 Vaccination in Patients Receiving Anti-CD20 Therapy. Journal of Clinical Medicine, 11(6), 1739.
https://doi.org/10.3390/jcm11061739
